38results about How to "Control the growth process" patented technology

The invention relates to a process and a device for rapidly growing a sapphire crystal material of a corundum system by virtue of a flame fusion method and belongs to the field of processes and devices for preparing crystals of the corundum system by virtue of the flame fusion method. By improvement on the crystal growth process, the rapid growth method is effectively broken through, the difficulty of not large growth size of the crystal is completely solved, the production efficiency is greatly improved and the production cost is further effectively controlled. Furthermore, at a high temperature of 2050 DEG C, the low-melting-point impurity in gamma-Al2O3 powder is gasified, the high-melting-point impurity is oxidized under an oxidizing atmosphere, the growth process of the crystal is fully realized, the repurification and recrystallization processes of the crystal are completed in fact, therefore, under the new process condition, the purity of alpha-Al2O3 sapphire crystal reaches up to 99.9998% and the requirement of users on the purity of the crystal is fully met. The whole set of device has simple and reasonable structure and design, is scientific and practical and suitable for being popularized in the industry and the crystal growth operation is efficiently performed in high quality manner.

The invention belongs to the field of researches on biomedicines and particularly relates to use of a human GSDMB gene in preparation of urinary bladder carcinoma treatment drugs as a target. According to the use of the human GSDMB gene and the related products, discovered by extensive and deep-going researches, through lowering expression of the human GSDMB gene by employing an RNAi method, the propagation of urinary bladder carcinoma cells can be effectively inhibited, apoptosis can be effectively promoted, and a growth process of a urinary bladder carcinoma can be effectively controlled. AnsiRNA provided by the invention or an siRNA sequence containing nucleic acid construct and slow virus can be used for specifically inhibiting a rate of propagation of the urinary bladder carcinoma cells, promoting the apoptosis of the urinary bladder carcinoma cells, inhibiting transferring of the urinary bladder carcinoma cells, inhibiting invasion of the urinary bladder carcinoma cells and inhibiting growth of the urinary bladder carcinoma so as to treat the urinary bladder carcinoma, and thus, a new direction is opened up for urinary bladder carcinoma treatment.

The invention belongs to the field of biological medicine research, and specifically relates to an application of a human RSPH14 gene as a target in preparation of a lung cancer treatment drug or a lung cancer diagnosis drug. According to the invention, results of wide and deep research find that effective inhibition to proliferation of lung cancer cells, promotion of apoptosis and effective control to the growth process of the lung cancer can be realized after the expression of the human RSPH14 gene is down-regulated by adopting an RNAi method. The siRNA or the nucleic acid construct and theslow virus containing the siRNA sequence provided by the invention can specifically inhibit the proliferation rate of the lung cancer cells, influence the cycle of the lung cancer cells, promote apoptosis of the lung cancer cells and inhibit the growth of the lung cancer, so the lung cancer is treated, and a new direction is opened up for treatment of the lung cancer.

The invention belongs to the field of biomedicine research, and specifically relates to an application of a human DUS4L gene as a target in preparation of a lung cancer therapeutic drug. Through extensive and in-depth research, results find that after an RNAi method is used to down-regulate the expression of the human DUS4L gene, proliferation of lung cancer cells can be effectively inhibited, cell apoptosis can be promoted, and the growth process of lung cancer can be effectively controlled. An siRNA or a nucleic acid construct containing an siRNA sequence and lentivirus provided by the invention can specifically inhibit the proliferation ability of the lung cancer cells, inhibit cloning of the lung cancer cells, affect a cycle of the lung cancer cells, promote apoptosis of the lung cancer cells, and inhibit growth of the lung cancer cells, thereby treating the lung cancer and opening up a novel direction for treatment of the lung cancer.

The invention belongs to the field of biological medicine research, and particularly relates to application of a human SHCBP1 gene used as a target in preparing a thyroid cancer treatment medicine orpreparing a thyroid cancer diagnosis medicine. Through the broad and deep research, the invention discovers that after the expression of the human SHCBP1 gene is down-regulated by adopting an RNAi method, the multiplication of thyroid cancer cells can be effectively inhibited, the cell apoptosis is promoted, and the growth process of thyroid cancer can be effectively controlled. The siRNA or a nucleic acid building body and a slow virus containing the siRNA can specifically inhibit a multiplication capacity of the thyroid cancer cells, inhibit a tumor formation capacity of the thyroid cancer cells in a human body, promote the thyroid cancer cell apoptosis, inhibit the cloning of the thyroid cancer cells, inhibit a thyroid cancer cell metastasis capacity, inhibit a thyroid cancer cell transfer capacity and change the period distribution of the thyroid cancer cells so as to treat the thyroid cancer, so that a new direction is opened for thyroid cancer treatment.

The invention belongs to the field of biomedical research, and particularly relates to application of human HIST1H2BK gene as a target in preparation of drugs used for treating liver cancer. It is found through wide and deep research that proliferation of liver cancer cells can be effectively inhibited, apoptosis can be promoted and the growth process of liver cancer can be effectively controlledafter the expression of human HIST1H2BK gene is down-regulated by adopting an RNAi method. A siRNA provided by the invention, or a nucleic acid construct and lentivirus containing the siRNA sequence can specifically inhibit the proliferation rate of liver cancer cells, promote apoptosis of liver cancer cells, inhibit cloning of liver cancer cells and inhibit growth of liver cancer cells, so that liver cancer is treated, and a new direction is provided for liver cancer treatment.

The present invention belongs to the field of biological medicine research and specifically relates to an application of a human PSMD7 gene serving as a target to preparation of a drug for treating pancreatic cancer. Found by extensive and deep research, after the expression of the human PSMD7 gene is reduced by adopting an RNAi method, the proliferation of pancreatic cancer cells may be effectively inhibited, cell apoptosis is promoted, and the growth process of the pancreatic cancer may be effectively controlled. siRNA or a nucleic acid construct containing an siRNA sequence and lentivirus provided by the present invention is capable of specifically inhibiting the proliferation capacity of the pancreatic cancer cells, the cloning of the pancreatic cancer cells, the apoptosis of the pancreatic cancer cells, the metastasis capacity of the pancreatic cancer cells and the growth of the pancreatic cancer, thereby treating pancreatic cancer and opening up a new direction for treating pancreatic cancer.

The invention belongs to the field of biopharmaceutical research, and particularly relates to an application of a human IMPA2 gene as a target to preparation of drugs for treating cervical cancer or drugs for diagnosis of cervical cancer. Through wide and deep research, the inventor finds that after an RNAi method is adopted for reducing the expression of the human IMPA2 gene, proliferation of cervical carcinoma cells can be effectively restrained, apoptosis is promoted, and growth process of the cervical cancer can be effectively controlled. siRNA or a nucleic acid constructor containing thesiRNA sequence, and a slow virus provided by the invention can specially restrain proliferation rate of the cervical carcinoma cells, can promote the apoptosis of the cervical carcinoma cells, can restrain cloning of the cervical carcinoma cells, can influence the period of the cervical carcinoma cells, and can restrain growth of the cervical cancer, so as to treat the cervical cancer and open upa new direction for treatment of the cervical cancer.

The invention belongs to the field of biomedical research, and particularly relates to an application of a human CCDC154 gene as a target in preparation of a liver cancer treatment drug. Through the wide and deep research, proliferation of liver cancer cells can be effectively inhibited after expression of the human CCDC154 gene is reduced by adopting an RNAi method, apoptosis is promoted, and thegrowth process of liver cancer can be effectively controlled. The siRNA or a nucleic acid construct containing the siRNA sequence and the lentivirus provided by the invention can specifically inhibitthe proliferation rate and proliferation activity of liver cancer cells, promote apoptosis of the liver cancer cells, inhibit cloning of the liver cancer cells and inhibit growth of liver cancer, sothat liver cancer is treated, and a new direction is opened up for liver cancer treatment.

The present invention belongs to the field for preparing composite ferro-electricity thin films by adopting sol-gel method.Said low temperature preparation method for composite thin films in accordance with the present invention is as follows: above all, preparing a precursor solution using sol-gal process and spin-coating a thin film with desirable thickness on the substrate Pt / Ti / SiO2 / Si and Ti at heat treating temperature of 300-400 DEG C for each thin film, then impregnating the thin film into a hydrothermal solution of 90-300 DEG C for 10-30 h, putting the thin film at a pure oxygen entironment of 1-35 MPa for a treatment for 10-30 hours, sputtering aurum on its surface for acting as an upper electrode. Said process in accordance with the present invention has a low preparing temperature and resolves the compatible technical problems of ferro-electricity film membrane and semi-conductor integrated circuit process. In addition, during thin film crystal grain growth at hydrothermal and high pressure oxygen conditions, the defect is reduced and then ferro-electricity thin film with high performances is obtained.

The invention belongs to the field of biological medicine research, and particularly relates to application of a human CFAP65 gene serving as a target in preparation of gastric cancer treatment drugs or gastric cancer diagnosis drugs. Through extensive and deep researches, proliferation of gastric cancer cells can be effectively inhibited after expression of the human CFAP65 gene is down-regulated by adopting an RNAi method, and the growth process of gastric cancer can be effectively controlled. The siRNA or the nucleic acid construct containing the siRNA sequence and the lentivirus provided by the invention can specifically inhibit the proliferation rate of gastric cancer cells and inhibit the growth of the gastric cancer, so that the gastric cancer is treated, and a new direction is opened up for the treatment of the gastric cancer.

The invention belongs to the field of biological medicine research, and particularly relates to application of a human DSN1 gene as a target in preparation of gastric cancer treatment drugs or gastric cancer diagnosis drugs. Through extensive and deep research, proliferation of gastric cancer cells can be effectively inhibited after expression of the human DSN1 gene is reduced by adopting an RNAi method, cell apoptosis is promoted, and the growth process of gastric cancer can be effectively controlled. The siRNA or the nucleic acid construct containing the siRNA sequence and the lentivirus provided by the invention can specifically inhibit the proliferation capacity of gastric cancer cells and inhibit the growth of gastric cancer, so that the gastric cancer is treated, and a new direction is opened up for gastric cancer treatment.

The invention belongs to the field of biomedical research, and particularly relates to application of a human UAP1L1 gene as a target in preparation of gastric cancer treatment drugs or gastric cancerdiagnosis drugs. It is found through extensive and intensive researches that after the expression of the human UAP1L1 gene is down-regulated by adopting an RNAi method, the proliferation of gastric cancer cells can be effectively inhibited, the apoptosis can be promoted, and the growth process of gastric cancer can be effectively controlled. The siRNA or the nucleic acid construct containing thesiRNA sequence and the lentivirus provided by the invention can specifically inhibit the proliferation rate of gastric cancer cells, promote apoptosis of the gastric cancer cells, inhibit tumor formation of the gastric cancer cells, inhibit cloning of the gastric cancer cells and inhibit growth of the gastric cancer, so that the gastric cancer is treated, and a new direction is opened up for treatment of the gastric cancer.

The invention relates to a method for preparing non-lead ferro-electricity film, wherein it comprises that: immerging film into water solution at 90-350Deg. C for 10-30h; splashing on upper electrode.The inventive film as Ba(Zr,Ti)O3(BZT), Ba(Ti,Sr)O3(BST), etc has warm reaction temperature, low energy consumption and wide application, while it can control reaction temperature, time, pressure, formula and pH value adjust the reaction and crystal growth. The inventive film can be used to prepare non-volatile memory, infrared detector, etc.

The invention belongs to the field of biomedical research, and specifically relates to the use of human LSM5 gene as a target in the preparation of colorectal cancer treatment drugs. After extensive and in-depth research, the present invention finds that the RNAi method can effectively inhibit the proliferation of colorectal cancer cells, promote cell apoptosis, and effectively control the growth process of colorectal cancer after down-regulating the expression of human LSM5 gene. The siRNA provided by the present invention or the nucleic acid construct containing the siRNA sequence, and the lentivirus can specifically inhibit the proliferation rate and proliferation ability of colorectal cancer cells, promote the apoptosis of colorectal cancer cells, inhibit the cloning of colorectal cancer cells, and inhibit the cloning of colorectal cancer cells. Cancer growth, so as to treat colorectal cancer, open up a new direction for the treatment of colorectal cancer.

The invention belongs to the field of biomedical research, and particularly relates to application of a human DEPDC1 gene as a target in preparation of tongue squamous cell carcinoma treatment drugs or tongue squamous cell carcinoma diagnosis drugs. Through wide and deep research, it is found that proliferation of tongue squamous cell carcinoma cells can be effectively inhibited and cell apoptosisis promoted after expression of a human DEPDC1 gene is lowered through an RNAi method, so that the growth process of tongue squamous cell carcinoma can be effectively controlled. The siRNA or the nucleic acid construct containing the siRNA sequence and the lentivirus provided by the invention can specifically inhibit the proliferation rate of tongue squamous cell carcinoma cells, promote apoptosis of the tongue squamous cell carcinoma cells, inhibit cloning of the tongue squamous cell carcinoma cells, influence the period of the tongue squamous cell carcinoma cells and inhibit growth of the tongue squamous cell carcinoma cells, so that the tongue squamous cell carcinoma is treated, and a new direction is opened up for tongue squamous cell carcinoma treatment.

The invention belongs to the field of research of biomedicines, and particularly relates to application of a human DNAJC24 gene as a target to preparation of medicines for treating lung cancers or medicines for diagnosing the lung cancers. Based on extensive and profound researching finding, by adopting a RNAi method, expression of the human DNAJC24 is regulated-down, so that proliferation of thelung cancer cells can be effectively inhibited and cell apoptosis is promoted, and a growth progress of the lung cancers can be effectively controlled. According to the siRNA or a nucleic acid construction body including an siRNA sequence and chronic viruses provided by the invention, the proliferation velocity of the lung cancer cells can be specifically inhibited, the cell apoptosis of the lungcancers is promoted, cell cloning of the lung cancers is inhibited, cell invasion of the lung cancers is inhibited, cell transferring of the lung cancers is inhibited, and growth of the lung cancers is inhibited, so that the lung cancers can be treated, and a new direction is developed for treatment of the lung cancers.

The invention belongs to the field of biological medicine research, and particularly relates to an application of a human EME1 gene serving as a target in preparing a treatment medicament of nasopharyngeal carcinoma. According to extensive and deep research, after expression of the human EME1 gene is downregulated by adopting an RNAi method, proliferation of nasopharyngeal carcinoma cells can be effectively inhibited, apoptosis is promoted, and thus a growth process of nasopharyngeal carcinoma can be effectively controlled. An siRNA provided by the invention or a nucleic acid construct containing the siRNA sequence, and lentivirus can specifically inhibit the proliferation rate of nasopharyngeal carcinoma cells, promote apoptosis of the nasopharyngeal carcinoma cells, inhibit metastasis ofthe nasopharyngeal carcinoma cells, inhibit invasion of the nasopharyngeal carcinoma cells and inhibit growth of the nasopharyngeal carcinoma, so that nasopharyngeal carcinoma is treated, and a new direction is opened up for treatment of nasopharyngeal carcinoma.

The invention belongs to the field of biological medicine research, and particularly relates to application of a human IGFL3 gene serving as a target to preparation of gastric cancer treatment drugs or gastric cancer diagnosis drugs. Through extensive and deep research, proliferation of gastric cancer cells can be effectively inhibited after expression of the human IGFL3 gene is down-regulated by adopting an RNAi method; and the growth process of gastric cancer can be effectively controlled. siRNA or a nucleic acid construct containing the siRNA sequence and a lentivirus provided by the invention can specifically inhibit the proliferation rate of the gastric cancer cells and inhibit the growth of the gastric cancer, so that the gastric cancer is treated, and a new direction is opened up for the treatment of the gastric cancer.

The invention,, which belongs to the field of biomedical research, particularly relates to application of a human TMEFF1 gene as a target in preparation of leukemia treatment drugs or leukemia diagnosis drugs. The wide and deep research finds that proliferation of leukemia cells can be effectively inhibited and apoptosis can be promoted after expression of the human TMEFF1 gene is down-regulated by adopting an RNAi method and thus the growth process of leukemia tumor cells can be effectively controlled. The siRNA or the nucleic acid construct or lentivirus containing the siRNA sequence can specifically inhibit the proliferation rate of leukemia tumor cells, promote apoptosis of the leukemia tumor cells, inhibit cloning of the leukemia tumor cells, influence the period of the leukemia tumorcells and inhibit development of leukemia, so that the leukemia is treated. Therefore, an novel direction is opened up for leukemia treatment.

The invention belongs to the field of biomedical research, and particularly relates to application of a human TTLL4 gene as a target in preparation of lung cancer treatment drugs. Results of wide anddeep research show that proliferation of lung cancer cells can be effectively inhibited, cell apoptosis is promoted and the growth process of the lung cancer can be effectively controlled after expression of the human TTLL4 gene is down-regulated by adopting an RNAi method. An siRNA or a nucleic acid construct and a lentivirus containing the siRNA sequence provided by the invention can specifically inhibit the proliferation rate of lung cancer cells, promote apoptosis of the lung cancer cells, inhibit cloning of the lung cancer cells, inhibit invasion of the lung cancer cells, inhibit metastasis of the lung cancer cells and inhibit growth of the lung cancer cells; therefore, a new direction is opened up for lung cancer treatment.

The invention belongs to the field of biomedical research, and particularly relates to application of a human EDDM3A gene as a target in preparation of gastric cancer treatment drugs. Results of wideand deep research show that the proliferation of gastric cancer cells can be effectively inhibited, cell apoptosis is promoted and the growth process of the gastric cancer can be effectively controlled after expression of the human EDDM3A gene is down-regulated by adopting an RNAi method. A siRNA or a nucleic acid construct and a lentivirus containing the siRNA sequence provided by the invention can specifically inhibit the proliferation rate of gastric cancer cells, promote apoptosis of the gastric cancer cells, inhibit cloning of the gastric cancer cells, inhibit the metastasis capability ofthe gastric cancer cells and inhibit growth of the gastric cancer, so the gastric cancer is treated, and a new direction is opened up for treatment of the gastric cancer.

The invention belongs to the field of biomedical research, and specifically relates to the use of human GSDMB gene as a target in the preparation of bladder cancer treatment drugs. After extensive and in-depth research, the present invention finds that the RNAi method can effectively inhibit the proliferation of bladder cancer cells, promote cell apoptosis, and effectively control the growth process of bladder cancer after down-regulating the expression of human GSDMB gene. The siRNA provided by the present invention or the nucleic acid construct containing the siRNA sequence, lentivirus can specifically inhibit the proliferation rate of bladder cancer cells, promote the apoptosis of bladder cancer cells, inhibit the metastasis of bladder cancer cells, inhibit the invasion of bladder cancer cells, and inhibit bladder cancer growth, thereby treating bladder cancer and opening up a new direction for bladder cancer treatment.

The invention belongs to the field of biomedical research, and particularly relates to application of a human CSPG5 gene as a target in preparation of liver cancer treatment drugs. Through wide and deep research, the invention finds that proliferation of liver cancer cells can be effectively inhibited, apoptosis is promoted and the growth process of liver cancer can be effectively controlled afterexpression of the human CSPG5 gene is down-regulated by adopting an RNAi method. The siRNA or a nucleic acid construct and lentivirus containing siRNA sequence provided by the invention can specifically inhibit the proliferation rate of the liver cancer cells, promote apoptosis of the liver cancer cells, inhibit cloning of the liver cancer cells, inhibit tumor formation of the liver cancer cellsand inhibit growth of the liver cancer, so that the liver cancer is treated, and a new direction is opened up for treatment of the liver cancer.

The invention belongs to the field of biomedical research, and particularly relates to application of a human EXOSC2 gene as a target in preparation of a drug for treating colorectal cancer. Through wide and deep research, it is found that: after expression of the human EXOSC2 gene is down-regulated by adopting an RNAi way, proliferation of colorectal cancer cells can be effectively inhibited, apoptosis is promoted and the growth process of colorectal cancer can be effectively controlled. The siRNA or a nucleic acid construct and lentivirus containing the siRNA sequence provided by the invention can specifically inhibit the proliferation rate of the colorectal cancer cells, promote apoptosis of the colorectal cancer cells, inhibit cloning of the colorectal cancer cells, inhibit invasion and metastasis of the colorectal cancer cells, and improve the survival rate of the colorectal cancer cells. Therefore, colorectal cancer is treated, and a new direction is opened up for colorectal cancer treatment.

The invention belongs to the technical field of preparing non-lead ferroelectric thin films by sol-gel method. The low-temperature preparation method of the alcohol-heat assisted ferroelectric thin film of the present invention is as follows: immerse the coated thin film in an alcohol solution at 120-300 DEG C for 10-30 hours at a pressure of 2-5 MPa, and then sputter the upper electrode. The alcohol thermal reaction condition of the present invention is relatively mild, the range of temperature adjustment is relatively wide, and the energy consumption is low. The reaction and crystal growth process can be effectively controlled by adjusting the reaction temperature, time and pressure, the composition of the solution and the pH value of the solution, so as to obtain the ideal material. At the same time, it effectively avoids the phenomenon of composition gradient and composition unevenness caused by the traditional direct use of hydrothermal method to prepare ferroelectric thin film on titanium substrate at low temperature, so as to effectively improve the material performance.

The invention belongs to the field of biological medicine research, and particularly relates to application of a human SUN3 gene serving as a target to preparation of gastric cancer treatment drugs or gastric cancer diagnosis drugs. Through extensive and deep researches, proliferation of gastric cancer cells can be effectively inhibited, cell apoptosis can be promoted and the growth process of gastric cancer can be effectively controlled after the expression of the human SUN3 gene is down-regulated by adopting an RNAi (Ribonucleic Acid Interfere) method. The siRNA or the nucleic acid construct containing the siRNA sequence and the lentivirus provided by the invention can specifically inhibit the proliferation capacity of gastric cancer cells and inhibit the growth of gastric cancer, so that the gastric cancer is treated, and a new direction is opened up for gastric cancer treatment.

The present invention relates to the field of biomedical research and particularly to uses of a human UBE2S gene as a target in preparation of glioma therapeutic drugs. Extensive and in-depth researches find that after an RNAi method down-regulates expression of the human UBE2S gene, proliferation of glioma cells can be effectively inhibited, cell apoptosis is promoted and a growth process of gliomas is effectively controlled. A provided shRNA or a nucleic acid construct containing the shRNA sequence and a lentivirus containing the shRNA sequence can specifically inhibit proliferation rate ofthe glioma cells, promoteapoptosis of the glioma cells, inhibit cloning of the glioma cells, inhibit growth of the gliomas, thus treat the gliomas and open up new directions for treatment of the gliomas.

The invention, which belongs to the field of biomedical research, particularly relates to application of a human LSM5 gene as a target in preparation of a colorectal cancer treatment drug. The wide and deep research discovers that the proliferation of colorectal cancer cells can be effectively inhibited and the apoptosis can be promoted by reducing the expression of the human LSM5 gene based on anRNAi method, thereby effectively controlling the growth process of colorectal cancer. According to the invention, the siRNA or the nucleic acid construct containing the siRNA sequence and the lentivirus can specifically inhibit the proliferation rate and proliferation capacity of colorectal cancer cells, promote apoptosis of the colorectal cancer cells, inhibit cloning of the colorectal cancer cells and inhibit growth of the colorectal cancer cells, so that the colorectal cancer is treated and a new direction is opened up for colorectal cancer treatment.